Immunotherapy: Bad B cells
Immunotherapy: Bad B cells, Published online: 25 January 2018; doi:10.1038/nrc.2018.7Immunotherapy: Bad B cells
Gastric cancer: Risk analysis
Gastric cancer: Risk analysis, Published online: 25 January 2018; doi:10.1038/nrc.2018.9Gastric cancer: Risk analysis
A matter of life and death: stem cell survival in tissue regeneration and tumour formation
A matter of life and death: stem cell survival in tissue regeneration and tumour formation, Published online: 19 January 2018; doi:10.1038/nrc.2017.122Stem cells are long-lived and possess unique mechanisms related to quiescence, DNA damage response and apoptosis that protect them throughout their lifespan and during tissue repair. These mechanisms may also have a role in cancer stem cells and tumorigenesis.
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
Targeting B cell receptor signalling in cancer: preclinical and clinical advances, Published online: 19 January 2018; doi:10.1038/nrc.2017.121In this Review, Burger and Wiestner describe the latest insights into B cell receptor (BCR) signalling with respect to its contribution to B cell malignancies and discuss how inhibitors that target kinases downstream of the BCR are changing treatment outcomes for patients with B cell neoplasms.
EMT in cancer
EMT in cancer, Published online: 12 January 2018; doi:10.1038/nrc.2017.118In this Viewpoint article, we asked four scientists working in the field of epithelial to mesenchymal transition (EMT) to provide their opinions on the role of this complicated phenomenon in cancer biology as well as the challenges of this fast-moving field and the directions it should take in the future.
Impact of oncogenic pathways on evasion of antitumour immune responses
Impact of oncogenic pathways on evasion of antitumour immune responses, Published online: 12 January 2018; doi:10.1038/nrc.2017.117This Review describes tumour cell-intrinsic oncogenic pathways implicated in tumour immune evasion and highlights the potential for targeting these pathways to overcome resistance to immunotherapy in various cancer types.